The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic adoption of HER2-targeting biologics, Roche/Genentech’s Perjeta (pertuzumab) and Kadcyla (T-DM1), has increased the barrier of entry for new emerging therapies. However, unmet need still exists for the treatment of advanced/metastatic HER2-positive breast cancer. Our content examines the key drivers of prescribing and analyzes the areas of significant commercial opportunities.
Questions Answered:
- What are the treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
- What are the prevailing areas of unmet need and opportunity in advanced/metastatic HER2-positive breast cancer?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new, advanced/metastatic HER2-positive breast cancer drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in February 2017.
Key companies: Roche/Genentech, Novartis
Key drugs: Perjeta, Kadcyla, Tykerb/Tyverb
Table of contents
- Breast Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU): Advanced/Metastatic HER2-Positive Breast Cancer
Author(s): Amy Yip, PhD
Amy Yip, Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Yip worked as an analyst at GlobalData where she worked on a number of disease reports within Healthcare and Pharmaceuticals, with a particular focus on oncology. Dr. Yip obtained her doctorate in molecular medicine at the Liggins Institute, University of Auckland, where she investigated the impact of aberrant neurotrophic factor expression on hormone signaling pathways in breast cancer cells. Dr. Yip also holds a BSc (Hons) degree, with first class honors in biomedical science, awarded by the University of Auckland, and has previously worked with Novartis in their New Zealand office.